Calcium channel blockers and the kidney

Clinical Cornerstone

Volumn 6, Issue 4, 2004, Pages 39-49

  Sica, Domenic ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; METOPROLOL; NIFEDIPINE; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ADRENERGIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PREFERENCE; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NONHUMAN; PROTEINURIA; RENAL PROTECTION; RISK REDUCTION;

EID: 15444375406     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(04)80077-2     Document Type: Article

References (36)

1. 2004 Annual Report. Atlas of end-stage renal disease in the United States October 21, 2004 United States Renal Data System http://www.usrds,org/adr.htm
2. Xue J.L. Ma J.Z. Louis T.A. Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the Year 2010 J Am Soc Nephrol. 127 2001 2753-2758
3. Coresh J. Astor B.C. Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population. Third National Health and Nutrition Examination Survey Am J Kidney Dis. 41 2003 1-12
4. Available at National Kidney Foundation New Guidelines Recommend Antihypertensive Therapy to Reduce Cardiovascular Disease Risk for Kidney Patients Accessed October 21, 2004 http://www.kidney.org/general/ news/printnews.cfm?id=226
5. Chobanian A.V. Bakis G.L. Black H.R. for the National High Blood Pressure Education Program Coordinating Committee Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206
6. The ALLRAT Officers and Co-ordinators for the ALLRAT Collaborative Group Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic.The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLRAT) JAMA 288 2002 1981-1997
7. Tuck M.L. Metabolic considerations in hypertension Am J Hypertens. 3 1990 3355-3655
8. Abstract Hori M. Saito F. Fittingoff M. Tuck M. Insulin attenuates angiotensin II mediated calcium mobilization in cultured rat vascular smooth muscle by depletion of intracellular calcium Clin Res. 39 1991 270
9. Abstract Bakris G.L. Akerstrom V. Re R. Insulin, angiotensin II, and endothelin: Effects on human mesangial cells Hypertension 16 1990 326A
10. Valentino V.A. Wilson M.D. Weart W. Bakris G.L. A perspective on converting enzyme inhibitors and calcium channel antagonists in diabetic renal disease Arch Intern Med. 151 1991 2367-2372
11. Anderson S. Rennke H.G. Garcia D.L. Brenner B.M. Short and long term effects of antihypertensive therapy in the diabetic rat Kidney Int. 36 1989 526-536
12. Zatz R. Dunn B.R. Meyer T.W. et al. Prevention of diabetic glomeralopathy by pharmacological amelioration of glomerular capillary hypertension J Clin Invest. 77 1986 1925-1930
13. Meyer T.W. Mechanisms of proteinuria in diabetic renal diseases Semin Nephrol. 10 1990 194-202
14. Dinneen S.F. Gerstein H.C. The Association of Microalbuminuria and Mortality in Non-InsulinDependent Diabetes Mellitus. A systematic overview of the literature Arch Intern Med. 157 1997 1413-1418
15. Niskanen L. Voutilanen R. Terasvirta M. et al. A prospective study of clinical and metabolic associates of proteinuria in patients with type 2 diabetes mellitus Diabet Med. 10 1993 543-549
16. Neil A. Hawkins M. Potok M. et al. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM Diabetes Care. 16 1993 996-1003
17. Stehouwer C.D.A. Nauta J.J.P. Zeldenrust G.C. et al. Urinary albumin excretion, cardiovascular disease and endothelial dysfunction in non-insulin dependent diabetes mellitus Lancet 340 1990 319-323
18. Steigler H. Standl E. Schulz K. et al. Morbidity, mortality and albuminuria in type 2 diabetic patients: A three-year prospective study of a random cohort in general practice Diabet Med. 9 1992 646-653
19. Patrick A.W. Leslie P.J. Clarke B.F. Frier B.M. The natural history and associations of microalbuminuria in type 2 diabetes during the first year after diagnosis Diabet Med. 7 1990 902-908
20. MacLeod J.M. Luteale J. Marshall S.M. Albumin excretion and vascular deaths in NIDDM Diabetologia 38 1995 610-616
21. Miettinen H. Haffner S.M. Lehto S. et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin dependent diabetic subjects Stroke 27 1996 2033-2039
22. Bakris G.L. Williams M. Dworkin L. et al. for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Preserving renal function in adults with hypertension and diabetes: A consensus approach Am J Kidney Dis. 36 2000 646-661
23. Vivian E.M. Goebig M.L. Slowing the progression of renal disease in diabetic patients Ann Phannacother 35 2001 452-463
24. Smith A.C. Toto R. Bakris G.L. Differential effects of calcium blockers on size selectivity of proteinuria in diabetic glomerulopathy Kidney Int. 54 1998 889-896
25. Holdaas H. Hartmann A. Lien M.G. et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubuluar transport function in insulin dependent dia betics with nephropathy J Intern Med. 229 1991 163-170
26. Agodoa L.Y. Appel L. Bakris G.L. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial JAMA 285 2001 2719-2728
27. Converse R.L. Jr Jacobsen T.N. Toto R.D. et al. Sympathetic overactivity in patients with chronic renal failure N Engl J Med. 327 1992 1912-1918
28. Frolich E.D. Apstein C. Chobanian A.V. et al. The heart in hypertension N Engl J Med. 327 1992 998-1008 [published correction appears in N Engl J Med. 1992;327:1768]
29. Kelm M. Schafer S. Mingers S. et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients J Hypertens 14 1996 1357-1364
30. Julius S. Sympathetic hyperactivity and coronary risk in hypertension Hypertension 21 1993 886-893
31. Ligtenberg G. Blankestijn P.J. Oey P.L. et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure N Engl J Med. 340 1999 1321-1328
32. Grossman E. Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure Am J Cardiol. 80 1997 1453-1458
33. Kloke H.J. Branten A.J. Huysmans F.T. Wetzels J.E. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers Kidney Int. 53 1998 1559-1573
34. Sica D.A. Combination calcium channel blocker therapy in the treatment of hypertension J Clin Hypertens 3 2001 322-327
35. Bakris G.L. Weir M.R. DeQuattro V. McMahon F.G. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int. 54 1998 1283-1289
36. Bakris G.L. Copley J.B. Vicknair N. et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney Int. 50 1996 1641-1650